Parkinson's disease drug delays onset of age-related macular degeneration

NewsGuard 100/100 Score

L-DOPA, a routine drug taken by patients suffering from Parkinson's disease, has been found to delay the onset of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

In a study investigating over 15 million people, individuals taking L-DOPA were significantly less likely to develop AMD, and when they did, the age of onset was significantly later. These results suggest L-DOPA may be useful in both preventing and delaying the disease.

AMD is the leading cause of irreversible visual loss in developed countries, causing deterioration of the central part of one's gaze.

Abstract Title: Inverse Association Between L-DOPA and Age-Related Macular Degeneration
Presentation Start/End Time: Tuesday, May 5, 8:30 - 10:15am
Location: Exhibit Hall
Abstract Number: 2818- C0046

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Placental DNA methylation patterns altered by pregnancy air pollution exposure, research reveals